Literature DB >> 6087328

Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.

J D Fingeroth, J J Weis, T F Tedder, J L Strominger, P A Biro, D T Fearon.   

Abstract

Identity of the Epstein-Barr virus (EBV) receptor with the complement receptor type 2 (CR2) was established in three sets of experiments using the monoclonal antibodies, HB-5 and anti-B2, which recognize a Mr 145,000 B-lymphocyte membrane protein that is CR2. First, the rank order for binding of fluoresceinated EBV to four lymphoblastoid cell lines (SB, JY, Raji, and Molt-4) was identical to the rank order for binding of HB-5 and anti-B2 by analytical flow cytometry. Second, pretreatment of cells with HB-5 followed by treatment with goat F(ab')2 fragments to mouse IgG blocked binding of fluoresceinated EBV on SB, a B-lymphoblastoid cell line. Virus attachment was not inhibited by HB-5 alone, second antibody alone, rabbit anti-C3b receptor, or UPC10 (an irrelevant monoclonal antibody). Third, transfer of CR2 from SB to protein A-bearing Staphylococcus aureus particles, to which HB-5 had been absorbed, conferred on them the specific ability to bind 125I-labeled EBV. We conclude that CR2 is the EBV receptor of human B lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6087328      PMCID: PMC345620          DOI: 10.1073/pnas.81.14.4510

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus.

Authors:  M Dolyniuk; R Pritchett; E Kieff
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

2.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Authors:  C B Lozzio; B B Lozzio
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

3.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

Authors:  J Minowada; T Onuma; G E Moore
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

4.  Autologous human B and T lymphoblastoid cell lines.

Authors:  I Royston; R W Smith; D N Buell; E S Huang; J S Pagano
Journal:  Nature       Date:  1974-10-25       Impact factor: 49.962

5.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

6.  Membrane receptor stripping confirms the association between EBV receptors and complement receptors on the surface of human B lymphoma lines.

Authors:  E Yefenof; G Klein
Journal:  Int J Cancer       Date:  1977-09-15       Impact factor: 7.396

7.  Human lymphocytes bear membrane receptors for C3b and C3d.

Authors:  A Eden; G W Miller; V Nussenzweig
Journal:  J Clin Invest       Date:  1973-12       Impact factor: 14.808

8.  A receptor for the third component of complement in the human renal glomerulus.

Authors:  M C Gelfand; M M Frank; I Green
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

9.  Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b.

Authors:  G D Ross; M J Polley; E M Rabellino; H M Grey
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

10.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

View more
  282 in total

1.  Analysis of Epstein-Barr virus (EBV) receptor CD21 on peripheral B lymphocytes of long-term EBV- adults.

Authors:  W J Jabs; M Paulsen; H J Wagner; H Kirchner; H Klüter
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

2.  Epstein-Barr virus infection of renal proximal tubule cells: possible role in chronic interstitial nephritis.

Authors:  J L Becker; F Miller; G J Nuovo; C Josepovitz; W H Schubach; E P Nord
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

3.  Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir.

Authors:  E A Gustafson; R F Schinazi; J D Fingeroth
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.

Authors:  J J Jakubik; M Saifuddin; D M Takefman; G T Spear
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

Review 5.  The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy.

Authors:  H J Delecluse; W Hammerschmidt
Journal:  Mol Pathol       Date:  2000-10

6.  B-lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression.

Authors:  Barbro Ehlin-Henriksson; John Gordon; George Klein
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

7.  Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.

Authors:  A Janz; M Oezel; C Kurzeder; J Mautner; D Pich; M Kost; W Hammerschmidt; H J Delecluse
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 8.  Epstein-Barr virus and gastric carcinoma.

Authors:  K Takada
Journal:  Mol Pathol       Date:  2000-10

9.  Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells.

Authors:  R S Haddad; L M Hutt-Fletcher
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

10.  Epstein-Barr virus (EBV)-containing nasopharyngeal carcinoma cells express the B-cell activation antigen blast2/CD23 and low levels of the EBV receptor CR2.

Authors:  M Billaud; P Busson; D Huang; N Mueller-Lantzch; G Rousselet; O Pavlish; H Wakasugi; J M Seigneurin; T Tursz; G M Lenoir
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.